(4-isopropylamino-2-methylsulfanyl-pyridine-5-yl)-methanol | 321690-72-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: (4-isopropylamino-2-methylsulfanyl-pyridine-5-yl)-methanol
• 英文别名: [4-isoropylamino-2-(methylsulfanyl)pyrimidine-5-yl]methanol；[2-(methylsulfanyl)-4-(propan-2-ylamino)pyrimidin-5-yl]methanol；(4-(isopropylamino)-2-(methylthio)pyrimidin-5-yl)methanol；[2-methylsulfanyl-4-(propan-2-ylamino)pyrimidin-5-yl]methanol
• CAS: 321690-72-6
• 化学式: C₉H₁₅N₃OS
• 分子量: 213.304
• InChiKey: RDTSYZYODWFYEM-UHFFFAOYSA-N

物化性质

• 沸点：
  404.5±35.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  83.3
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4-isopropylamino-2-methylsulfanyl-pyridine-5-yl)-methanol 在 manganese(IV) oxide 、 溶剂黄146 、 苄胺 作用下， 以 氯仿 为溶剂， 反应 30.0h， 生成 8-isopropyl-2-methylsulfanyl-7-oxo-pyrido[2,3-d]pyrimidine-6-carbonitrile
  参考文献：
  名称：

  Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)

  摘要：

  The success of imatinib, a BCR-ABL inhibitor for the treatment of chronic myelogenous leukemia, has created a great impetus for the development of additional kinase inhibitors as therapeutic agents. However, the complexity of cancer has led to recent interest in polypharmacological approaches for developing multikinase inhibitors with low toxicity profiles. With this goal in mind, we analyzed more than 150 novel cyano pyridopyrimidine compounds and identified structure-activity relationship trends that can be exploited in the design of potent kinase inhibitors. One compound, 8-cyclopentyl-2[-4-(4-methyl-piperazin-l-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x), was found to be the most active, inducing apoptosis of tumor cells at a concentration of approximately 30-100 nM. In vitro kinase profiling revealed that 7x is a multikinase inhibitor with potent inhibitory activity against the CDK4/CYCLIN D1 and ARKS kinases. Here, we report the synthesis, structure-activity relationship, kinase inhibitory profile, in vitro cytotoxicity, and in vivo tumor regression studies by this lead compound.

  DOI：

  10.1021/jm401073p
• 作为产物：
  描述：

  4-氯-2-甲硫基嘧啶-5-羧酸乙酯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 为溶剂， 反应 1.0h， 生成 (4-isopropylamino-2-methylsulfanyl-pyridine-5-yl)-methanol
  参考文献：
  名称：

  [EN] HETEROARYL COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS HÉTÉROARYLE ET UTILISATIONS ASSOCIÉES

  摘要：

  本发明涉及作为蛋白激酶抑制剂的化合物，这些化合物在ATP结合位点包含一个半胱氨酸残基。该发明还提供了包含一种或多种蛋白激酶抑制剂化合物的药用可接受组合物，以及使用所述组合物治疗癌症和癌的方法。

  公开号：

  WO2014144737A1

文献信息

• [EN] PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS PYRIMIDINES EN TANT QU'INHIBITEURS DE KINASE
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2014151682A1

  公开（公告）日：2014-09-25

  This disclosure relates to compounds, methods for their preparation, pharmaceutical compositions including these compounds and methods for the treatment of cellular proliferative disorders, including, but not limited to, cancer.

  这份披露涉及化合物、它们的制备方法、包括这些化合物的药物组合物以及治疗细胞增殖障碍的方法，包括但不限于癌症。
• [EN] NOVEL COMPOUNDS AS JNK KINASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS UTILISABLES EN TANT QU'INHIBITEURS DES JANUS KINASES
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015084936A1

  公开（公告）日：2015-06-11

  The present invention is directed to modulators, such as inhibitors, of JNK isoform 2 (JNK2) or isoform 3 (JNK3) comprising compounds of formula (I) or formula (II) as described herein. Compounds of the invention can be used for treatment of a medical disorder in a patient wherein modulation of JNK3 is medically indicated, such as when the disorder is Parkinsons disease (PD) Alzheimer's disease (AD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), myocardial infarction (MI), glaucoma, obesity, diabetes, cancer, rheumatoid arthritis, fibrotic disease, pulmonary fibrosis, kidney disease, liver inflammation, Crohns disease, hearing loss, Prader Willi syndrome, or a condition where modification of feeding behavior is medically indicated.

  本发明涉及调控剂，例如JNK同型2（JNK2）或同型3（JNK3）的抑制剂，包括如本文所述的公式（I）或公式（II）的化合物。 发明中的化合物可用于治疗患者中的医疗障碍，其中JNK3的调控在医学上有指示，例如当障碍是帕金森病（PD）、阿尔茨海默病（AD）、亨廷顿病（HD）、肌萎缩侧索硬化（ALS）、多发性硬化症（MS）、心肌梗死（MI）、青光眼、肥胖、糖尿病、癌症、类风湿性关节炎、纤维化疾病、肺纤维化、肾病、肝脏炎症、克罗恩病、听力损失、普拉德-威利综合症，或修改摄食行为在医学上有指示的状况。
• [EN] GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES À DOUBLE SUBSTITUTION GEM ET LEUR UTILISATION EN TANT QU'INHIBITEURS D'IDH
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2021089395A1

  公开（公告）日：2021-05-14

  The present invention relates to certain gem-disubstituted heterocyclic compounds, which modulate the activity of Isocitrate Dehydrogenase (IDH). The compounds of this invention are therefore useful in treating diseases caused by mutated IDH1 and/or mutated IDH2 enzyme and/or IDH1 wild type (wt) enzyme. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

  本发明涉及某些宝石二取代杂环化合物，其调节异柠檬酸脱氢酶（IDH）的活性。因此，本发明的化合物在治疗由突变的IDH1和/或突变的IDH2酶和/或IDH1野生型（wt）酶引起的疾病方面是有用的。本发明还提供了制备这些化合物的方法，包括这些化合物的药物组合物，以及利用包含这些化合物的药物组合物治疗疾病的方法。
• IDH突变体抑制剂及其用途
  申请人：微境生物医药科技（上海）有限公司

  公开号：CN113845528A

  公开（公告）日：2021-12-28

  本发明涉及一类式(1a)或式(1b)所示的化合物及其制备方法，及式(1a)或式(1b)化合物及其各光学异构体、各晶型、药学上可接受的盐作为IDH突变体不可逆抑制剂在抗肿瘤药物制备中的用途。
• Kinase inhibitors useful for the treatment of proliferative diseases
  申请人：Flynn L. Daniel

  公开号：US20080114006A1

  公开（公告）日：2008-05-15

  The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

  本发明涉及一种新型激酶抑制剂和调节剂化合物，用于治疗各种疾病。更具体地说，本发明涉及这样的化合物、激酶/化合物加合物、治疗疾病的方法以及合成化合物的方法。优选地，这些化合物对Raf激酶及其疾病多态性的激酶活性调节是有用的。本发明的化合物在哺乳动物癌症，特别是人类癌症，包括但不限于恶性黑色素瘤、结肠直肠癌、卵巢癌、乳头状甲状腺癌、非小细胞肺癌和间皮瘤的治疗中发挥作用。本发明的化合物也在治疗类风湿性关节炎和视网膜病变，包括糖尿病性视网膜神经病变和黄斑变性方面发挥作用。